Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LU AG09222

Next Previous
X
Search
Drug Profile

LU AG09222

Alternative Names: ALD 1910; Anti-PACAP-38-antibody - Lundbeck A/S; LU-AG09222; PACAP - Lundeback

Latest Information Update: 04 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alder Biopharmaceuticals
  • Developer Lundbeck A/S
  • Class Antiallergics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Pituitary adenylate cyclase-activating polypeptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Migraine
  • Discontinued Allergic rhinitis

Most Recent Events

  • 01 Sep 2024 Lundbeck A/S plans a phase I trial for Migraine (Combination therapy) in September 2024 (IV) (NCT06578585)
  • 01 Apr 2024 Phase-II clinical trials in Migraine (Prevention, Treatment-experienced) in USA (SC) (NCT06323928)
  • 26 Mar 2024 Lundbeck A/S plans a phase II PROCEED trial for Migraine (Prevention, Treatment-experienced) (SC), in April 2024 (NCT06323928)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top